Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firmonertinib Combined With Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Adenocarcinoma
NCT07878871Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Nov 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in lung adenocarcinoma, sponsored by Hunan Cancer Hospital. Primary endpoint: Objective Response Rate up to 36 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT07878871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07878871.